BioCentury | Mar 28, 2016
Financial News

Envisia Therapeutics financial update

Envisia Therapeutics Inc. , Research Triangle Park, N.C. Business: Ophthalmic Date announced: 2016-03-23 Note: Envisia raised $16.5 million in an extension of a series A round, bringing the total raised in the round to $41.5 million....
BioCentury | Oct 12, 2015
Clinical News

ENV515: Phase IIa data

...quarter, Envisia will start a 12-month trial to evaluate the long-term IOP-lowering effect of ENV515. Envisia Therapeutics Inc....
BioCentury | Oct 7, 2015
Clinical News

Envisia's ENV515 matches Travatan Z in glaucoma study

Envisia Therapeutics Inc. (Research Triangle Park, N.C.) said ENV515 met the primary endpoint in a Phase IIa trial to treat glaucoma. The extended-release formulation of travoprost significantly reduced intraocular pressure (IOP) in the dose-ranging study,...
BioCentury | Jun 19, 2015
Company News

Management tracks

...April. Nolan was CBO at InterMune Inc. , which Roche (SIX:ROG; OTCQX:RHHBY) acquired. Ophthalmic company Envisia Therapeutics Inc....
BioCentury | Apr 16, 2015
Company News

Management tracks

...and supplement company Equateq Ltd., which BASF AG (Xetra:BAS; LSE:BFA) acquired in 2012. Ophthalmology company Envisia Therapeutics Inc....
BioCentury | Mar 11, 2015
Company News

Management tracks

...He was CBO of Covagen AG , which was acquired by Johnson & Johnson (NYSE:JNJ). Envisia Therapeutics Inc....
BioCentury | Sep 15, 2014
Company News

Liquidia, Lq3 dental, drug delivery news

...testing. Lq3's CEO is Kyle Chenet, formerly VP of corporate development at Liquidia and Liquidia's Envisia Therapeutics Inc....
BioCentury | Jul 21, 2014
Emerging Company Profile

Envisia: Ophthalmic nanotechnology

...GA. ALLERGAN INC. (NYSE:AGN), IRVINE, CALIF. ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, ROCKVILLE, MD. ENVISIA THERAPEUTICS INC....
...ASX:PVA), WATERTOWN, MASS. ROCHE (SIX:ROG; OTCQX:RHHBY), BASEL, SWITZERLAND SENJU PHARMACEUTICAL CO. LTD., OSAKA, JAPAN Sidebars Envisia Therapeutics Inc....
BioCentury | Feb 20, 2014
Cover Story

Europe's upwelling

...Seragon Pharmaceuticals Inc. Cancer San Diego, Calif. $30.0 Pulmocide Ltd. Infectious disease London, U.K. $27.4 Envisia Therapeutics Inc....
BioCentury | Nov 18, 2013
Financial News

Envisia Therapeutics completes venture financing

Envisia Therapeutics Inc. , Research Triangle Park, N.C. Business: Ophthalmic Date completed: 11/12/13 Type: Venture financing Raised: $25 million Investors: Canaan Partners; New Enterprise Associates; Pappas Ventures; Morningside Technology Ventures; Wakefield Group WIR Staff Ophthalmic...
Items per page:
1 - 10 of 12
BioCentury | Mar 28, 2016
Financial News

Envisia Therapeutics financial update

Envisia Therapeutics Inc. , Research Triangle Park, N.C. Business: Ophthalmic Date announced: 2016-03-23 Note: Envisia raised $16.5 million in an extension of a series A round, bringing the total raised in the round to $41.5 million....
BioCentury | Oct 12, 2015
Clinical News

ENV515: Phase IIa data

...quarter, Envisia will start a 12-month trial to evaluate the long-term IOP-lowering effect of ENV515. Envisia Therapeutics Inc....
BioCentury | Oct 7, 2015
Clinical News

Envisia's ENV515 matches Travatan Z in glaucoma study

Envisia Therapeutics Inc. (Research Triangle Park, N.C.) said ENV515 met the primary endpoint in a Phase IIa trial to treat glaucoma. The extended-release formulation of travoprost significantly reduced intraocular pressure (IOP) in the dose-ranging study,...
BioCentury | Jun 19, 2015
Company News

Management tracks

...April. Nolan was CBO at InterMune Inc. , which Roche (SIX:ROG; OTCQX:RHHBY) acquired. Ophthalmic company Envisia Therapeutics Inc....
BioCentury | Apr 16, 2015
Company News

Management tracks

...and supplement company Equateq Ltd., which BASF AG (Xetra:BAS; LSE:BFA) acquired in 2012. Ophthalmology company Envisia Therapeutics Inc....
BioCentury | Mar 11, 2015
Company News

Management tracks

...He was CBO of Covagen AG , which was acquired by Johnson & Johnson (NYSE:JNJ). Envisia Therapeutics Inc....
BioCentury | Sep 15, 2014
Company News

Liquidia, Lq3 dental, drug delivery news

...testing. Lq3's CEO is Kyle Chenet, formerly VP of corporate development at Liquidia and Liquidia's Envisia Therapeutics Inc....
BioCentury | Jul 21, 2014
Emerging Company Profile

Envisia: Ophthalmic nanotechnology

...GA. ALLERGAN INC. (NYSE:AGN), IRVINE, CALIF. ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, ROCKVILLE, MD. ENVISIA THERAPEUTICS INC....
...ASX:PVA), WATERTOWN, MASS. ROCHE (SIX:ROG; OTCQX:RHHBY), BASEL, SWITZERLAND SENJU PHARMACEUTICAL CO. LTD., OSAKA, JAPAN Sidebars Envisia Therapeutics Inc....
BioCentury | Feb 20, 2014
Cover Story

Europe's upwelling

...Seragon Pharmaceuticals Inc. Cancer San Diego, Calif. $30.0 Pulmocide Ltd. Infectious disease London, U.K. $27.4 Envisia Therapeutics Inc....
BioCentury | Nov 18, 2013
Financial News

Envisia Therapeutics completes venture financing

Envisia Therapeutics Inc. , Research Triangle Park, N.C. Business: Ophthalmic Date completed: 11/12/13 Type: Venture financing Raised: $25 million Investors: Canaan Partners; New Enterprise Associates; Pappas Ventures; Morningside Technology Ventures; Wakefield Group WIR Staff Ophthalmic...
Items per page:
1 - 10 of 12